Table. Vaccines that are routinely recommended in pregnancy: inactivated vaccines
See also the disease-specific chapters in this Handbook for more details.
| Vaccine | Recommendation | Comments |
|---|---|---|
| Influenza | Recommended for all pregnant women at any stage of pregnancy, particularly those who will be in the 2nd or 3rd trimester during the influenza season | Clinical trial data and observational studies show no increased risk of congenital defects or adverse effects in the fetuses of women who received influenza vaccine during pregnancy. Pregnancy increases the risk of severe influenza. Influenza immunisation protects the mother, and also protects her newborn baby in the first few months after birth.2 See Influenza. |
| dTpa (diphtheria-tetanus-acellular pertussis) | Recommended as a single dose between mid 2nd trimester and early 3rd trimester of each pregnancy (ideally at 20–32 weeks) | Vaccination during pregnancy reduces the risk of pertussis in pregnant women and their young infants by 90%.2,3 Studies have found no evidence of an increased risk of adverse pregnancy outcomes related to pertussis vaccination during pregnancy.4-9 Optimal protection is provided when the vaccine is given soon after 20 weeks and protection is lower if given within 2 weeks of birth. See Pertussis for more details. |
| Respiratory syncytial virus (Abrysvo only) |
Recommended as a single dose between 28 and 36 weeks gestation. Advice on potential repeat vaccination during subsequent pregnancies will be provided in the future as more data become available. The need for revaccination with each subsequent pregnancy is anticipated based on first principles and experience with other vaccines recommended in pregnancy. |
A clinical trial found vaccine efficacy of 57% in infants born to mothers who received Abrysvo, against hospitalisation from RSV for up to 6 months.10 There was no conclusive evidence of a significant difference in preterm births or other adverse pregnancy outcomes in the Abrysvo trials. Vaccination before 28 weeks is not recommended as a precautionary approach due to an imbalance in the number of preterm births and neonatal deaths seen in low- and middle-income countries during another discontinued maternal RSV vaccine trial.11 Vaccination beyond 36 weeks is permitted; however, protection is lower if given within 2 weeks of birth. See respiratory syncytial virus (RSV) for more details. |
Page history
Last updated
Last reviewed